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Abstract
Background: COPD is characterized by variability in exercise capacity and physical activity (PA), and acute exacerbations
(AEs). Little is known about the relationship between daily step count, a direct measure of PA, and the risk of AEs, including
hospitalizations.
Methods: In an observational cohort study of 169 persons with COPD, we directly assessed PA with the StepWatch Activity
Monitor, an ankle-worn accelerometer that measures daily step count. We also assessed exercise capacity with the 6-minute
walk test (6MWT) and patient-reported PA with the St. George’s Respiratory Questionnaire Activity Score (SGRQ-AS). AEs and
COPD-related hospitalizations were assessed and validated prospectively over a median of 16 months.
Results: Mean daily step count was 580463141 steps. Over 209 person-years of observation, there were 263 AEs (incidence
rate 1.361.6 per person-year) and 116 COPD-related hospitalizations (incidence rate 0.5661.09 per person-year). Adjusting
for FEV1 % predicted and prednisone use for AE in previous year, for each 1000 fewer steps per day walked at baseline, there
was an increased rate of AEs (rate ratio 1.07; 95%CI=1.003–1.15) and COPD-related hospitalizations (rate ratio 1.24;
95%CI=1.08–1.42). There was a significant linear trend of decreasing daily step count by quartiles and increasing rate ratios
for AEs (P=0.008) and COPD-related hospitalizations (P=0.003). Each 30-meter decrease in 6MWT distance was associated
with an increased rate ratio of 1.07 (95%CI=1.01–1.14) for AEs and 1.18 (95%CI=1.07–1.30) for COPD-related
hospitalizations. Worsening of SGRQ-AS by 4 points was associated with an increased rate ratio of 1.05 (95%CI=1.01–
1.09) for AEs and 1.10 (95%CI=1.02–1.17) for COPD-related hospitalizations.
Conclusions: Lower daily step count, lower 6MWT distance, and worse SGRQ-AS predict future AEs and COPD–related
hospitalizations, independent of pulmonary function and previous AE history. These results support the importance of
assessing PA in patients with COPD, and provide the rationale to promote PA as part of exacerbation-prevention strategies.
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Introduction
COPD is the fourth most common cause of death in the US,
affects 5% of US adults, and accounts for a large number of
hospitalizations [1,2]. Persons with COPD have significantly
reduced exercise capacity, measured by clinic-based tests such as
the 6-minute walk test (6MWT), and reduced physical activity
(PA), directly measured with accelerometers or assessed by
questionnaires [3–10]. In addition, lower 6MWT distance and
lower daily step count, a direct and novel measure of PA, are
significant predictors of all-cause mortality in COPD [11,12].
COPD is also characterized by acute exacerbations (AEs) which
result in poorer health-related quality of life (HRQL), a faster
decline in lung function, and increased mortality [13–17].
Hospitalizations due to AEs account for a large portion of
COPD-related medical costs [18]. To date, the key known factors
predicting AEs and hospitalizations are the degree of airflow
obstruction and history of prior AEs [13,19–23]. Since these
factors are usually already maximized with medical pharmacolog-
ical therapy, there is a need to identify additional factors that can
be targeted for intervention [20].
PLOS ONE | www.plosone.org 1 April 2013 | Volume 8 | Issue 4 | e60400Persons with COPD have a wide range of PA levels which may
be potentially modifiable. The relationship between PA and risk of
AEs and COPD-related hospitalizations is unclear [24]. Prior
studies have been limited because they assessed PA only by self-
report which is notoriously overestimated, did not account for
prior AE history, or studied only severe AEs that resulted in
hospitalizations [8,9,19,25–26]. In this report, our primary aim is
to examine the relationship between PA directly measured with an
accelerometer and risk of moderate and severe AEs and COPD-
related hospitalizations. We hypothesize that lower daily step
count predicts greater risk of AEs and COPD-related hospitaliza-
tions, independent of lung function and prior AEs. As a secondary
aim, we assess 6MWT, a commonly used clinic-based test of
exercise capacity, and patient-report of PA with the St. George’s
Respiratory Questionnaire Activity Score (SGRQ-AS), and
examine their relationships with risk of AEs and COPD-related
hospitalizations.
Methods
Ethics Statement
The protocol was approved by the VA Boston Healthcare
System Committee on Human Research, and written informed
consent obtained from each participant.
Study Design and Participants
This work arises from a study which has been previously
published, and the subjects reported here include the 127 subjects
previously reported [27]. Between January 2009 and November
2011, we recruited eligible participants who were over 40 years of
age and who had received care for COPD in the VA Boston
Healthcare System general pulmonary clinics. The diagnosis of
COPD was defined as having a smoking history of at least 10 pack-
years and a ratio of forced expiratory volume in one second (FEV1)
to forced vital capacity of ,0.70 or evidence of emphysema on
chest computed tomography. Exclusion criteria were inability to
ambulate and occurrence of an AE within 4 weeks of enrollment
[15].
At baseline, information about demographics, medical history,
and medications was obtained. Subjects reported being at their
usual clinical status at the time of enrollment. Participants
underwent measurement of FEV1, using an Eaglet spirometer
(nSpire Health, Inc.) [28]. The 6MWT was performed following
ATS guidelines, except that a practice 6MWT was not done [29].
Patient-reported measures included assessments of dyspnea using
the modified Medical Research Council (MMRC) scale [30],
HRQL using the SGRQ, with scores ranging from 0–100 and
lower scores indicating better HRQL [31], and depression using
the Beck Depression Inventory [32]. The SGRQ has been
recommended for use as a patient-reported measure of functional
status, and we present the SGRQ-AS [3]. We considered a history
of previous AEs as a potential confounder. To assess the past
occurrence of AEs, participants were asked if they had received
treatment with prednisone for breathing problems in the year
prior to enrollment [13,15,23,33].
The StepWatch Activity Monitor (SAM) (Orthocare Innova-
tions, Seattle, WA, USA), an ankle-worn accelerometer, measures
step counts from all walking–as part of PA and exercise in persons
with COPD. We have shown the SAM to be accurate and valid in
persons with COPD [27]. In this study, participants wore the
SAM for 14 consecutive days and were instructed to perform their
usual physical activities and exercise. The SAM does not provide
on-instrument feedback of steps walked. Subjects returned the
SAM to study staff by mail. Study staff downloaded the step
counts, which are date and time stamped, via a docking station.
No-wear days, defined as ones with ,200 steps recorded and
,8 hours of wear time, were excluded from the analysis [27,34].
Subjects with $8 no-wear days were excluded.
Study Outcomes
The primary outcomes were AEs and COPD-related hospital-
izations. AE was defined as ‘‘a complex of respiratory symptoms
(increased or new onset) of at least two of the following: cough,
sputum, wheezing, dyspnea, or chest tightness lasting 3 or more
days, requiring a course of treatment with antibiotics or systemic
steroids [15,35].’’ We included moderate AEs that required
treatment in the outpatient setting and severe AEs that required
hospitalizations. We included hospitalizations due to AE and/or
pneumonia as COPD-related hospitalizations. Hospitalizations
due to other pulmonary or cardiac causes were excluded. After the
baseline visit, participants were prospectively queried on the use of
oral corticosteroids and/or antibiotics and hospitalizations for lung
problems using a structured telephone interview every 3 months
for a median of 16 months. Participant reports were verified with
medical records. Two investigators, blinded to baseline charac-
teristics, reviewed subject responses and medical records to
determine if an AE had occurred and the primary cause of
hospitalizations. Independence of events was assured by consid-
ering a new event only if subjects had been off oral corticosteroids
and/or antibiotics for at least 14 days following the previous AE or
COPD-related hospitalization [15,36].
Statistical Analysis
Descriptive results are reported as means 6 SD or percentages,
as appropriate. Comparisons of descriptive characteristics were
performed with the use of unpaired T tests or Fisher’s Exact Test,
as appropriate. The incidence rates of AEs and COPD-related
hospitalizations were determined by dividing the numbers of AEs
and COPD-related hospitalizations by the person-years of follow-
up. Predictors of AEs and COPD-related hospitalizations were
assessed using negative binomial models with the logarithm of
observation time as an offset variable (PROC GENMOD, SAS
9.2, SAS Institute; Cary, NC) [23,36]. In this approach, daily step
count was examined as a continuous variable and the rate ratio
calculated by exponentiating the regression coefficient. In separate
models, daily step count was categorized in quartiles. Linear trend
P values were derived using an ordinal variable coded based on the
median of each step-count quartile. Variables significant at the
P,0.05 level in univariate analyses were subsequently examined in
multivariate models. All multivariate models included FEV1 %
predicted and prednisone for AE in previous year as covariates. To
put the results into clinical context, we calculated the rate ratios
and 95% confidence intervals corresponding to published mini-
mum clinically important differences (MCIDs) for the 6MWT and
SGRQ-AS [4,37–40].
Results
Study Participants
A total of 188 persons with COPD were enrolled. The analysis
excluded 12 subjects who did not have baseline step-count data
because 5 were noncompliant with step-count monitoring (had $8
no-wear days), 5 had no baseline step-count data due to an AE
during the monitoring period, 1 lost the SAM, and 1 had SAM
accuracy ,90%. An additional 7 subjects did not participate in
follow-up telephone calls. There were no differences in FEV1 %
predicted, 6MWT distance, SGRQ Total Score (SGRQ-TS),
SGRQ-AS, or MMRC dyspnea score among the 19 subjects
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persons with baseline and follow-up data, 167 were males, mean
age was 7168 years, mean FEV1 was 1.5560.57 L (54620%
predicted) [41], and mean daily step count was 580463141
(Table 1). All 4 GOLD stages were represented; most subjects
were GOLD II (46%) and GOLD III (33%) [2]. Twenty subjects
(12%) had participated in a previous pulmonary rehabilitation
program and 43 (25%) used supplemental oxygen. Four subjects
died during follow-up.
Figure 1 shows the distribution of average daily step count. Of
2,366 days monitored, only 3% (n=81) met the definition of a no-
wear day. Compared to subjects with average daily step count $
the median average of 5,232, those with a daily step count ,5,232
were significantly older, and had higher body-mass index (BMI),
lower FEV1 % predicted, lower 6MWT distance, higher MMRC
dyspnea score, worse SGRQ-TS, worse SGRQ-AS, and higher
frequency of supplemental oxygen use and coronary artery disease
(Table 1). In the 51 subjects (30%) who had used prednisone for
breathing problems in the year prior to enrollment, mean daily
step count was 495662608, which was significantly lower than the
617063288 steps per day observed in the 118 subjects who had
not used prednisone (P=0.012).
Outcome Assessment
Over 209 person-years of follow-up, there were 263 AEs
(incidence rate 1.361.6 per person-year) in 99 of 169 subjects
(59%). Of these, 167 AEs were experienced by 54 of the 85
persons with daily step count , the median, and 96 AEs were
experienced by 45 of the 84 persons with daily step count $ the
median. There were 116 COPD-related hospitalizations (inci-
dence rate 0.5661.09 per person-year) in 54 of 169 subjects (32%).
Of these, 79 hospitalizations were experienced by 37 persons with
daily step count , the median, and 37 hospitalizations were
experienced by 17 persons with daily step count $ the median.
224 AEs (85%) and 108 COPD-related hospitalizations (93%)
were verified with medical records.
In univariate models, lower daily step count was a significant
predictor of higher rates of future AEs and COPD-related
hospitalizations (Table 2). There was a significant linear trend of
decreasing daily step count by quartiles and increasing rate ratios
for AEs (P=0.0003) and COPD-related hospitalizations
(P=0.0003). Lower 6MWT distance and worse SGRQ-AS were
also significantly associated with higher rate ratios for AEs and
COPD-related hospitalizations (Table 2). Lower FEV1 % predict-
ed and prednisone for AE in previous year were significantly
associated with a higher rate ratio for AEs and COPD-related
hospitalizations. Worse SGRQ-TS and supplemental oxygen use
also significantly predicted future AEs. Age, BMI, pack-years,
history of diabetes mellitus or coronary artery disease, MMRC
dyspnea score, Beck’s depression index, and season were not
related to the risk of AEs and COPD-related hospitalizations.
In multivariate models adjusting for FEV1 % predicted and
prednisone for AE in previous year, for each 1000 fewer steps per
day walked at baseline, there was a significantly increased rate of
AEs (rate ratio 1.07; 95%CI=1.003–1.15) and COPD-related
hospitalizations (rate ratio 1.24; 95%CI=1.08–1.42) (Table 3).
The rate ratio for AEs and COPD-related hospitalizations in each
step-count quartile was significantly increased compared to the
rate ratio for persons in the highest step-count quartile (Table 3).
Compared to persons in the highest step-count quartile, persons in
the lowest quartile had a rate ratio of 2.26 (95%CI=1.25–4.08)
for AEs and 6.01 (95%CI=1.99–18.2) for COPD-related
hospitalizations. There was a significant linear trend of decreasing
daily step count by quartiles and increasing rate ratios for AEs
(P=0.008) and COPD-related hospitalizations (P=0.003).
Similarly, in multivariate models, lower 6MWT distance and
worse SGRQ-AS were significant predictors of AEs and COPD-
related hospitalizations, independent of FEV1 % predicted and
prednisone for AE in previous year (Tables 4 and 5). A decrease of
30 meters (37) in 6MWT distance was associated with an
increased rate ratio of 1.07 (95%CI=1.01–1.14) for AEs and
1.18 (95%CI=1.07–1.30) for COPD-related hospitalizations. A
worsening of SGRQ-AS by 4 points [42] was associated with an
increased rate ratio of 1.05 (95%CI=1.01–1.09) for AEs and 1.10
(95%CI=1.02–1.17) for COPD-related hospitalizations. SGRQ-
TS and supplemental oxygen use were not significantly associated
with risk of AEs and COPD-related hospitalizations in multivar-
iate models, adjusting for FEV1 % predicted and prednisone for
AE in previous year.
Discussion
Our results demonstrate that persons with COPD with lower
daily step count have significantly higher rate ratios for AEs and
COPD-related hospitalizations, independent of FEV1 % predicted
and previous exacerbation history. These novel findings are
further supported by the significant linear associations over the
entire range of daily step counts with rate ratios for AEs and
COPD-related hospitalizations. Our results strongly support the
rationale to study PA promotion as part of future exacerbation-
prevention interventions in COPD.
A strength of our study is the use of 3 complementary measures
of functional status to assess exacerbation risk prospectively in the
same cohort. We examined daily step count as a direct measure of
PA in the community, 6MWT as a clinic-based test of exercise
capacity, and the SGRQ-AS as a patient-reported assessment of
PA. Our data demonstrate that the relationship between PA and
exacerbation risk is robust since daily step count predicts AE and
COPD-related hospitalizations in a similar fashion as 6MWT
distance and SGRQ-AS. Our results add to the evidence that daily
step count is an important clinical characteristic of persons with
COPD that can complement the 6MWT and questionnaire
assessment of PA [43].
We focus on daily step count because it can be easily and
directly translatable from the research to the clinical setting. Daily
step count is a meaningful and relevant metric that, from the
public health standpoint, can help define PA recommendations
and promote PA in persons with COPD [44]. Healthcare
providers and patients understand what it means to target PA
goals to increase daily step counts. It is not feasible for providers to
advise patients to improve their 6MWT distance since it is a clinic-
based measure of exercise capacity that has little meaning to an
individual. We previously published a pilot study showing that it is
feasible for patients to monitor daily step count with a pedometer,
and that persons with COPD can increase their walking with step-
count goals [45].
In addition, directly measured daily step count overcomes
limitations of questionnaire assessments of PA. First, it is well-
known that persons overestimate self-reported physical activity.
Second, the SGRQ-AS is used primarily in research settings and
has no obvious meaning to most clinicians and all patients. Finally,
prior studies using self-reported PA to examine risk for AEs/
hospitalizations crudely characterized PA as $2 hours per week
versus ,2 hours per week [8,25]. In contrast, directly measured
daily step count allows accurate characterization of the relation-
ship between PA and risk of AEs and hospitalizations so that future
intervention studies can be appropriately designed.
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*
Total Mean Daily Step,5232
+ Mean Daily Step$5232
+
n=169 n=85 n=84
Age
{ 71687 3 686 9 68
Body-mass index
{ 29663 0 672 8 65
Marital status
{
Married 76 (45) 46 (54) 30 (36)
Not married 93 (55) 39 (46) 54 (64)
Race
White 156 (92) 79 (93) 77 (92)
Non-White 13 (8) 6 (7) 7 (8)
Employment status
{
Full or part-time 20 (12) 5 (6) 15 (18)
Not working 42 (25) 18 (21) 24 (28)
Retired 107 (63) 62 (73) 45 (54)
Education
Some/Completed high school 76 (45) 40 (47) 36 (43)
Some/Completed college or higher 93 (55) 45 (53) 48 (57)
Alcohol use
$1 day/week 52 (31) 30 (35) 22 (26)
,1 day/week 117 (69) 55 (65) 62 (74)
Prior participation in pulmonary rehabilitation
{ 20 (12) 16 (19) 4 (5)
Supplemental oxygen use
{ 43 (25) 32 (38) 11 (13)
Prednisone for AE in previous year 51 (30) 31 (36) 20 (24)
Coronary artery disease
{ 63 (37) 39 (46) 24 (29)
Congestive heart failure 23 (14) 15 (18) 8 (10)
Diabetes mellitus 48 (28) 24 (28) 24 (29)
Pack-years 68637 70633 66640
FEV1 (liters)
{ 1.5560.57
1 1.4260.57 1.6860.55
"
FEV1, % predicted
{ 54620
1 51620 58620
"
GOLD stage
{
I1 6 ( 1 0 )
1 6 (7) 10 (12)
"
II 77 (46) 35 (41) 42 (51)
III 56 (33) 28 (33) 28 (34)
IV 19 (11) 16 (19) 3 (4)
6MWT distance (meters)
{ 3716100 319690 423681
MMRC dyspnea score
{
0–1 68 (40) 20 (24) 48 (57)
2–4 101 (60) 65 (76) 36 (43)
SGRQ-TS
{ 45620 49618 42620
SGRQ-AS
{ 63623 69619 57625
Beck depression index 12611 11611 12611
Medication for COPD
`
Any short-acting b2 agonist 150 (89) 78 (92) 72 (86)
Any short-acting muscarinic antagonist 29 (17) 18 (21) 11 (13)
Any long-acting b2 agonist 108 (64) 56 (66) 52 (62)
Any long-acting muscarinic antagonist 125 (74) 63 (74) 62 (74)
Any inhaled corticosteroid 115 (68) 61 (72) 54 (64)
AE denotes acute exacerbation; FEV1 forced expiratory volume in 1 second; GOLD Global Initiative for Chronic Obstructive Lung Disease; 6MWT 6-minute walk test; MMRC
Modified Medical Research Council; SGRQ-TS St. George’s Respiratory Questionnaire Total Score; and SGRQ-AS St. George’s Respiratory Questionnaire Activity Score.
*Mean 6 standard deviation for continuous variables and N (%) for categorical variables.
+The median average daily step count is 5,232.
{P Value,0.05; Unpaired T-test (continuous variables) or Fisher’s Exact Test (categorical variables).
`Information on medication was self-reported; subjects may have been taking more than one medication.
1N=168.
"N=83.
doi:10.1371/journal.pone.0060400.t001
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PLOS ONE | www.plosone.org 4 April 2013 | Volume 8 | Issue 4 | e60400To date, history of previous AEs has emerged as the strongest
predictor of future AEs and hospitalizations, and FEV1 %
predicted has been consistently found to be a significant predictor
of future AEs and hospitalizations [13,19–23]. However, spirom-
etry alone is an inadequate predictor as there is a subset of patients
with severely reduced FEV1 % predicted who do not experience
frequent AEs [13]. We have identified daily step count, 6MWT
distance, and SGRQ-AS as significant predictors of risk of AEs
and COPD-related hospitalizations, independent of FEV1 %
predicted. Furthermore, we show that lower daily step count,
lower 6MWT distance, and worse SGRQ-AS predict future AEs
and COPD-related hospitalizations, regardless of previous AE
history. Our results that 6MWT and SGRQ-AS are independent
predictors of risk of AEs and COPD-related hospitalizations are
consistent with previously published studies. Two previous studies
have shown that 6MWT distance predicts AEs in univariate, but
not multivariate models [13,46]. A lower 6MWT distance has
been shown to predict hospitalizations in univariate but not
multivariate models, which did not account for previous AEs or
hospitalizations [19]. Epidemiological studies have shown a
significant trend of decreasing physical activity, assessed by self-
report, and increased risk of COPD-related admissions and
hospitalization readmissions for COPD exacerbation [8,9]. We
calculated the rate ratios corresponding to a range of potentially
clinically relevant changes in 6MWT to put our results into greater
clinical context (Tables 4 and 6) [4,37–40]. Similarly, we
calculated the rate ratios that correspond to a 4-point worsening
in SGRQ-AS. As MCID data for the SGRQ-AS are not available,
we extrapolated the MCID of 4 units based on the SGRQ-TS
[31,42].
A host of variables including chronic hypercapnia, pulmonary
hypertension, hypoxemia, current smoking, older age, lower BMI,
higher MMRC dyspnea score, and season have been inconsis-
tently associated with AEs or hospitalizations in previous studies
[19–23,47]. We did not find an association between pack-years,
age, BMI, MMRC dyspnea score, oxygen use, prior pulmonary
rehabilitation, or season with AEs and COPD-related hospital-
izations. Our results may reflect differences in age, gender, and
FEV1 among cohorts and we accounted for potential confounding
factors. Our study extends the generalizability and significance of
the current literature by (1) including persons with all COPD
severities, (2) studying moderate AEs as well as severe AEs, (3)
directly measuring PA, and (4) including persons with COPD who
have never participated in pulmonary rehabilitation [25,26,46].
Compared to other studies, our higher mean % predicted FEV1
is due to the fact that we included persons with all stages of
COPD, including GOLD I or mild COPD. Our study was
designed to be as inclusive as possible to increase generalizability,
and thus included persons with all GOLD stages of COPD
severity. Our cohort has similar frequencies of moderate COPD
(GOLD II) and very severe (GOLD IV) as previously published
clinical trials in COPD such as Evaluation of COPD Longitudi-
nally to Identify Predictive Surrogate Endpoints (ECLIPSE) [13]
and Understanding the Potential Long-term Impacts on Function
with Tiotropium (UPLIFT) [48], supporting that our cohort
represents the entire range of disease severity. Interestingly, our
results are obtained in a cohort that has been largely medically
optimized, indicating the importance of factors other than
pharmacological therapy in managing exacerbation risk. Sixty-
Figure 1. Distribution of mean daily step count. Median is 5,232 steps per day, N=169.
doi:10.1371/journal.pone.0060400.g001
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PLOS ONE | www.plosone.org 5 April 2013 | Volume 8 | Issue 4 | e60400four percent of subjects were using a long-acting b2 agonist and
74% a long-acting muscarinic antagonist.
The main strengths of our study include our use of 3
complementary measures of functional status, our validated
method of measuring daily step count, our structured approach
to obtaining a prospective history of AEs and COPD-related
hospitalizations, and the high percentage of events confirmed with
medical records. We used an a priori event-based definition of AE
that was easy for patients to recall and had blinded adjudication of
events [15,36]. Given our clear definition of AEs, every 3 month
follow-up, and medical chart review, it is unlikely that we missed
any AEs as we defined them. Much of the current literature has
reported on risk factors only for severe AEs that resulted in
hospitalizations [8,9,19,20,23,25,26]. Our inclusion of moderate
AEs that required medication treatment but not hospitalization
broadens the significance of our results, as most AEs do not result
in hospitalizations. It is possible that we did not capture mild AEs
not requiring treatment. Nevertheless, the incidence rate for AEs
of 1.3 per person-year observed in our study is comparable to
incidence rates reported in the placebo groups of large COPD
clinical trials [13,33,48].
Some limitations need to be considered. We did not capture
upper extremity activities. However, total daily PA has been
shown to be closely related to leg activity in persons with COPD
[49]. We did not measure the intensity of walking or activities such
as swimming or bicycling that do not result in step counts.
Previously, devices used to assess PA have reported relatively
obscure units such as ‘‘activity units’’ which are difficult to
understand and do not allow comparison between studies. The
devices used in previous studies include (1) the RT3 accelerometer
Table 2. Univariate Associations with Number of Acute Exacerbations and COPD-Related Hospitalizations.
Characteristics Acute Exacerbations COPD-Related Hospitalizations
Rate Ratio 95% CI P Value Rate Ratio 95% CI P Value
Age (per year increase) 1.02 0.99–1.04 0.13 1.03 0.995–1.07 0.08
Body-mass index (per kg/m
2 increase) 0.996 0.96–1.03 0.81 0.96 0.92–1.01 0.16
Mean Daily Step Count (per 1000 step decrease) 1.11 1.04–1.19 0.003 1.29 1.13–1.49 0.0003
Mean daily step Quartiles
(ref $6956)
,3667 3.00 1.68–5.36 0.0002 8.69 2.92–25.8 ,0.0001
3667#6,5232 2.62 1.46–4.71 0.001 6.94 2.31–20.9 0.0006
5232#6,6956 2.36 1.30–4.27 0.005 6.80 2.25–20.6 0.0007
P for linear trend 0.0003 0.0003
6MWT distance 1.10 1.03–1.17 0.003 1.21 1.10–1.34 0.0002
(per 30-meter decrease
1)
SGRQ-AS (per 4-point worsening
1) 1.07 1.03–1.12 0.0005 1.12 1.04–1.19 0.002
FEV1, % predicted
{ 1.13 1.02–1.25 0.01 1.22 1.05–1.42 0.008
(per 10% decrease in % of predicted value)
Prednisone for AE in previous year (ref=no) 2.44 1.66–3.58 ,0.0001 2.16 1.17–4.00 0.01
SGRQ-TS 1.07 1.03–1.12 0.002 1.09 1.01–1.17 0.02
(per 4-point worsening)
MMRC dyspnea score 2–4 (ref=0–1) 1.47 0.97–2.22 0.07 1.67 0.89–3.14 0.11
Supplemental oxygen use (ref=no) 1.56 1.01–2.40 0.04 1.50 0.77–2.91 0.23
Pack-years 1.003 0.998–1.01 0.27 1.001 0.99–1.01 0.87
Diabetes mellitus
(ref=no) 1.14 0.73–1.79 0.55 1.23 0.63–2.41 0.54
Coronary artery disease 1.08 0.71–1.65 0.72 0.90 0.47–1.73 0.75
(ref=no)
Beck depression index 1.01 0.99–1.02 0.50 1.005 0.98–1.03 0.74
Season of step count monitoring
(ref=Summer)
Fall 0.85 0.51–1.40 0.52 0.98 0.45–2.13 0.97
Winter 0.80 0.40–1.61 0.54 0.61 0.20–1.88 0.39
Spring 0.79 0.44–1.41 0.43 1.14 0.48–2.73 0.76
6MWT denotes 6-minute walk test; SGRQ-AS St. George’s Respiratory Questionnaire Activity Score; FEV1 forced expiratory volume in 1 second; AE acute exacerbation;
SGRQ-TS St. George’s Respiratory Questionnaire Total Score; MMRC Modified Medical Research Council; and ref reference group.
1Rate ratios calculated for a MCID of 30 m [37] for 6MWT and 4 units [42] for SGRQ-AS. The regression coefficients (SE) in natural log risk per 30-m decrease in 6MWT
predicting AEs and COPD-related hospitalizations are 0.0976 (0.0323) and 0.1946 (0.0516), respectively. The regression coefficients (SE) in natural log risk per 4-unit
decrease in SGRQ-AS predicting AEs and COPD-related hospitalizations are 0.0712 (0.0206) and 0.1091 (0.0347), respectively.
{N=168.
doi:10.1371/journal.pone.0060400.t002
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PLOS ONE | www.plosone.org 7 April 2013 | Volume 8 | Issue 4 | e60400that reports physical activity movements using ‘‘vector magnitude
units’’ (VMUs); (2) the Dynaport activity monitor that reports time
spent in walking, cycling, standing, sitting, or lying; and (3) the
SenseWear armband that reports total daily energy expenditure
which is then converted to a ‘‘physical activity level’’ [6,7]. Depew
et al. have shown that daily step count is a surrogate for physical
activity level, with daily step count ,4,580 reflecting severe
inactivity or physical activity level ,1.40 [50]. Since walking is a
common PA and steps per day is a measure of PA that is easy to
understand, steps per day is a clinically relevant and practical
variable to monitor in persons with COPD.
We did not track daily step count during follow-up, but we have
previously shown that daily step count does not change
significantly over time in stable COPD [27]. Therefore misclas-
sification of baseline step counts is unlikely. The follow-up period,
a median of 16 months, could be considered short, but it was
sufficient to see a significant association between daily step count
and risk of AEs and COPD-related hospitalizations. In addition,
new events, such as a stroke or hip replacement, which may affect
walking are more likely to occur with a longer follow-up period,
confounding the relationship between daily step count and risk of
AEs and COPD-related hospitalizations.
We considered a history of previous AEs requiring therapy with
corticosteroids as a potential confounder since AEs tend to recur in
the same person. To assess AEs in the year prior to study
enrollment, we asked, ‘Have you used prednisone for breathing
problems in the past year?’ This approach of adjustment for
previous exacerbations has been used in previously published
studies [13,15,23]. The report of prednisone use before study entry
is distinct from the definition of AEs assessed prospectively, ‘‘a
complex of respiratory symptoms (increased or new onset) of at
least two of the following: cough, sputum, wheezing, dyspnea, or
chest tightness lasting 3 or more days, requiring a course of
treatment with antibiotics or systemic steroids,’’ as previously used
in large clinical studies of COPD exacerbations [13,15,23].
We did not collect information on the time period between
participation in a pulmonary rehabilitation program and partic-
ipation in this study. In case the results are biased because the 20
subjects who had ever participated in pulmonary rehabilitation
had an increased daily step count, we performed a sensitivity
analysis excluding the 20 subjects. We found similar results, and
thus, included the 20 subjects in the final results. Finally, these
results need to be confirmed in larger studies, and intervention
studies are needed to assess whether increases in daily step count
reduce AE and COPD-related hospitalization risk in persons with
COPD.
In conclusion, these results provide evidence for the importance
of daily step count as a determinant of health status and
exacerbation risk in persons with COPD. Our results suggest that
there is a subgroup of COPD patients with low daily step count
who have significantly increased risk of AEs and COPD-related
hospitalizations, regardless of their % predicted FEV1.W e
speculate that the ‘‘low walker’’ may be a novel COPD phenotype.
In contrast to other proposed phenotypes defined by frequent
exacerbations, radiologic differences, or persistent systemic
inflammation, the PA phenotype is potentially amenable to
behavioral modification [13,47,51].
Table 4. Multivariate Model of Associations between 6MWT distance and Number of Acute Exacerbations and COPD-Related
Hospitalizations Adjusting for FEV1 % Predicted and Prednisone for AE in Previous Year.
*
Acute Exacerbations COPD-Related Hospitalizations
Rate Ratio 95% CI P value Rate Ratio 95% CI P value
FEV1, % predicted (per 10% increase in % of
predicted value)
1.06 0.96 1.17 0.23 1.15 0.99 1.33 0.06
Prednisone for AE in previous year (ref=no) 2.14 1.46 3.14 0.0001 1.71 0.95 3.07 0.08
6MWT distance (per 30-meter decrease
1) 1.07 1.01 1.14 0.03 1.18 1.07 1.30 0.001
FEV1 denotes forced expiratory volume in 1 second; AE acute exacerbation; ref reference group; and 6MWT denotes 6-minute walk test.
*N=168.
1Rate ratios calculated for a MCID of 30 m for 6MWT. The regression coefficients (SE) in natural log risk per 30-m decrease in 6MWT distance predicting AEs and COPD-
related hospitalizations are 0.0674 (0.0308) and 0.1624 (0.0502), respectively.
doi:10.1371/journal.pone.0060400.t004
Table 5. Multivariate Model of Associations between SGRQ-AS and Number of Acute Exacerbations and COPD-Related
Hospitalizations Adjusting for FEV1 % Predicted and Prednisone for AE in Previous Year.
*
Acute Exacerbations COPD-Related Hospitalizations
Rate Ratio 95% CI P value Rate Ratio 95% CI P value
FEV1, % predicted (per 10% increase in % of predicted value) 1.07 0.97 1.17 0.17 1.17 1.02 1.36 0.03
Prednisone for AE in previous year (ref=no) 1.99 1.34 2.95 0.0006 1.60 0.87 2.94 0.13
SGRQ-AS (per 4-point worsening
1) 1.05 1.01 1.09 0.02 1.10 1.02 1.17 0.008
FEV1 denotes forced expiratory volume in 1 second; AE acute exacerbation; ref reference group; and SGRQ-AS St. George’s Respiratory Questionnaire Activity Score.
*N=168.
1Rate ratios calculated for a MCID of 4 units for SGRQ-AS. The regression coefficients (SE) in natural log risk per 4-unit decrease in SGRQ-AS predicting AEs and COPD-
related hospitalizations are 0.0484 (0.0202) and 0.0923 (0.0347), respectively.
doi:10.1371/journal.pone.0060400.t005
Daily Step Count Predicts Acute COPD Exacerbations
PLOS ONE | www.plosone.org 8 April 2013 | Volume 8 | Issue 4 | e60400Author Contributions
Conceived and designed the experiments: MM EG. Performed the
experiments: NW. Analyzed the data: MM MT DG EG. Wrote the
paper: MM MT NW DG EG.
References
1. Mannino DM, Braman S (2007) The epidemiology and economics of chronic
obstructive pulmonary disease. Proc Am Thorac Soc 4:502–506.
2. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, et al. (2007) Global Initiative
for Chronic Obstructive Lung Disease. Global strategy for the diagnosis,
management, and prevention of chronic obstructive pulmonary disease: GOLD
executive summary. Am J Respir Crit Care Med 176:532–555.
3. Kocks JW, Asijee GM, Tsiligianni IG, Kerstjens HA, van der Molen T (2011)
Functional status measurement in COPD: a review of available methods and
their feasibility in primary care. Prim Care Respir J 20:269–725.
4. Puhan MA, Chandra D, Mosenifar Z, Ries A, Make B, et al. (2011) The
minimal important difference of exercise tests in severe COPD. Eur Respir J
37:784–790.
5. Moy ML, Matthess K, Stolzmann K, Reilly J, Garshick E (2009) Free-living
physical activity in COPD: assessment with accelerometer and activity checklist.
J Rehabil Res Dev 46:277–286.
6. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, et al. (2005)
Characteristics of physical activities in daily life in chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 171:972–977.
7. Watz H, Waschki B, Meyer T, Magnussen H (2009) Physical activity in patients
with COPD. Eur Respir J 33:262–272.
8. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Anto JM (2006) Regular
physical activity reduces hospital admission and mortality in chronic obstructive
pulmonary disease: a population based cohort study. Thorax 61:772–778.
9. Garcia-Aymerich J, Farrero E, Fe ´lez MA, Izquierdo J, Marrades RM, et al.
(2003) Risk factors of readmission to hospital for a COPD exacerbation: a
prospective study. Thorax 58:100–105.
10. Waschki B, Spruit MA, Watz H, Albert PS, Shrikrishna D, et al. (2012) Physical
activity monitoring in COPD: compliance and associations with clinical
characteristics in a multicenter study. Respir Med 106:522–530.
11. Martinez FJ, Foster G, Curtis JL, Criner G, Weinmann G, et al. (2006)
Predictors of mortality in patients with emphysema and severe airflow
obstruction. Am J Respir Crit Care Med 173:1326–1334.
12. Waschki B, Kirsten A, Holz O, Mu ¨ller KC, Meyer T, et al. (2011) Physical
activity is the strongest predictor of all-cause mortality in patients with COPD. A
prospective cohort study. Chest 140:331–342.
13. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mu ¨llerova H, et al. (2010)
Susceptibility to exacerbation in chronic obstructive pulmonary disease.
N Engl J Med 363:1128–1138.
14. Rodriguez-Roisin R (2000) Toward a consensus definition for COPD
exacerbation. Chest 117:398S–401S.
15. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, et al. (2011)
Azithromycin for prevention of exacerbations of COPD. N Engl J Med
365:689–698.
16. Connors AF, Jr, Dawson NV, Thomas C, Harrell FE, Jr, Desbiens N, et al.
(1996) Outcomes following acute exacerbation of severe chronic obstructive lung
disease. Am J Respir Crit Care Med 154:959–967.
17. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, et al. (1998)
Effect of exacerbation on quality of life in patients with chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 157:1418–1422.
18. Strassels SA, Smith DH, Sullivan SD, Mahajan PS (2001) The costs of treating
COPD in the United States. Chest 119:344–352.
19. Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E (1999)
Predictive factors of hospitalization for acute exacerbation in a series of 64
patients with chronic obstructive pulmonary disease. Am J Respir Crit Care
Med 159:158–164.
20. Garcia-Aymerich J, Monso ´ E, Marrades RM, Escarrabill J, Fe ´lez MA, et al.
(2001) Risk factors for hospitalization for a chronic obstructive pulmonary
disease exacerbation. Am J Respir Crit Care Med 164:1002–1007.
21. Niewoehner DE, Lokhnygina Y, Rice K, Kuschner WG, Sharafkhaneh A, et al.
(2007) Risk indexes for exacerbations and hospitalizations due to COPD. Chest
131:20–28.
22. Jenkins CR, Celli B, Anderson JA, Ferguson GT, Jones PW, et al. (2012)
Seasonality and determinants of moderate and severe COPD exacerbations in
the TORCH study. Eur Respir J 39:38–45.
23. Wells JM, Washko GR, Han MK, Abbas N, Nath H, et al. (2012) Pulmonary
arterial enlargement and acute exacerbations of COPD. N Engl J Med 367:913–
921.
24. Seidel D, Cheung A, Suh ES, Raste Y, Atakhorrami M, et al. (2012) Physical
inactivity and risk of hospitalization for chronic obstructive pulmonary disease.
Int J Tuberc Lung Dis 16:1015–1019.
25. Benzo RP, Chang CCH, Farrell MH, Kaplan R, Ries A, et al. (2010) Physical
activity, health status and risk of hospitalization in patients with severe chronic
obstructive pulmonary disease. Respiration 80:10–18.
26. Spruit MA, Polkey MI, Celli B, Edwards LD, Watkins ML, et al. (2012)
Predicting outcomes from 6-minute walk distance in chronic obstructive
pulmonary disease. J Am Med Dir Assoc 13:291–297.
27. Moy ML, Danilack VA, Weston NA, Garshick E (2012) Daily step counts in a
US cohort with COPD. Respir Med 106:962–969.
28. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. (2005)
Standardisation of spirometry. Eur Respir J 26:319–338.
29. ATS Committee on Proficiency Standards for Clinical Pulmonary Function
Laboratories. ATS statement: guidelines for the six-minute walk test (2002) Am J
Respir Crit Care Med 166:111–117.
30. Mahler DA, Wells CK (1988) Evaluation of clinical methods for rating dyspnea.
Chest 93:580–586.
31. Jones PW, Quirk FH, Baveystock CM, Littlejohns P (1992) A self-complete
measure of health status for chronic airflow limitation. The St. George’s
Respiratory Questionnaire. Am Rev Respir Dis 145:1321–1327.
32. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for
measuring depression. Arch Gen Psychiatry 4:561–571.
33. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, et al. (2007)
Salmeterol and fluticasone propionate and survival in chronic obstructive
pulmonary disease. N Engl J Med 356:775–789.
34. Matthews CE, Hagstromer M, Pober DM, Bowles HR (2012) Best practices for
using physical activity monitors in population-based research. Med Sci Sports
Exerc 44:S68–S76.
35. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA Jr, et al. (2005)
Prevention of exacerbations of chronic obstructive pulmonary disease with
tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized
trial. Ann Intern Med 143:317–326.
36. Aaron SD, Fergusson D, Marks GB, Suissa S, Vandemheen KL, et al. (2008)
Counting, analysing and reporting exacerbations of COPD in randomised
controlled trials. Thorax 63:122–128.
37. Polkey MI, Spruit MA, Edwards LD, Watkins ML, Pinto-Plata V, et al. (2012)
Six minute walk test in COPD: Minimal clinically important difference for death
or hospitalization. Am J Respir Crit Care Med 187:382–386.
38. Holland AE, Hill CJ, Rasekaba T, Lee A, Naughton MT, et al. (2010) Updating
the minimal important difference for six-minute walk distance in patients with
chronic obstructive pulmonary disease. Arch Phys Med Rehabil 91:221–225.
39. Puhan MA, Mador MJ, Held U, Goldstein R, Guyatt GH, et al. (2008)
Interpretation of treatment changes in 6-minute walk distance in patients with
COPD. Eur Respir J 32:637–643.
40. Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH (1997) Interpreting
small differences in functional status: the six minute walk test in chronic lung
disease patients. Am J Respir Crit Care Med 155:1278–1282.
Table 6. Calculated Rate Ratios for Published MCIDs for 6MWT Distance.
6MWT Distance MCIDs Acute Exacerbations COPD-Related Hospitalizations
Rate Ratio 95% CI Rate Ratio 95% CI
Per 25 meter decrease [4,38] 1.058 1.006–1.112 1.145 1.055–1.243
Per 35 meter decrease [39] 1.082 1.008–1.161 1.209 1.078–1.356
Per 54 meter decrease [40] 1.129 1.013–1.258 1.340 1.122–1.599
MCID denotes minimum clinically important difference; and 6MWT 6-minute walk test.
doi:10.1371/journal.pone.0060400.t006
Daily Step Count Predicts Acute COPD Exacerbations
PLOS ONE | www.plosone.org 9 April 2013 | Volume 8 | Issue 4 | e6040041. Hankinson JL, Odencrantz JR, Fedan KB (1999) Spirometric reference values
from a sample of the general U.S. population. Am J Respir Crit Care Med
159:179–187.
42. Jones PW (2005) St. George’s Respiratory Questionnaire: MCID. COPD 2:75–
79.
43. vanGestel AJR, Clarenbach CF, Stowhas AC, Rossi VA, Sievi NA, et al. (2012)
Predicting daily physical activity in patients with chronic obstructive pulmonary
disease. PLOS ONE 7:e48081.
44. Lee IM, Buchner DM (2008) The importance of walking to public health. Med
Sci Sports Exerc 40:S512–S518.
45. Moy ML, Weston NA, Wilson EJ, Hess ML, Richardson CR (2012) A pilot
study of an Internet walking program and pedometer in COPD. Respir Med
106:1342–1350.
46. Faganello MM, Tanni SE, Sanchez FF, Pelegrino NR, Lucheta PA, et al. (2010)
BODE index and GOLD staging as predictors of 1-year exacerbation risk in
chronic obstructive pulmonary disease. Am J Med Sci 339:10–14.
47. Han MK, Kazerooni EA, Lynch DA, Liu LX, Murray S, et al. (2011) Chronic
obstructive pulmonary disease exacerbations in the COPD Gene study:
associated radiologic phenotypes. Radiology 261:274–282.
48. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, et al. (2008) A 4-year trial of
tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359:1543–
1554.
49. Walker PP, Burnett A, Flavahan PW, Calverley PMA (2008) Lower limb activity
and its determinants in COPD. Thorax 63:683–689.
50. Depew ZS, Novotny PJ, Benzo RP (2012) How many steps are enough to avoid
severe physical inactivity in patients with chronic obstructive pulmonary disease?
Respirology 17:1026–1027.
51. Agustı ´ A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, et al. (2012)
Persistent systematic inflammation is associated with poor clinical outcomes in
COPD: A novel phenotype. PLOS ONE 7:e37483.
Daily Step Count Predicts Acute COPD Exacerbations
PLOS ONE | www.plosone.org 10 April 2013 | Volume 8 | Issue 4 | e60400